Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker.
Samsung Biologics
Private
Samsung Biologics is a South Korean contract development and manufacturing organization (CDMO) providing end-to-end services for biopharmaceutical products, from cell line development to commercial manufacturing. It operates one of the world's largest single-site biomanufacturing facilities in Songdo, South Korea.
Company Info
Sector:Biopharmaceutical CDMO
Headquarters:Songdo, Incheon, South Korea
Founded:2011
Website:samsungbiologics.com
Funding Round:Parent: Samsung Group
Total Funding:Public-company-level (multi-billion $ capacity build-out)
Funding & Investor Relations
Notable Investors
- Samsung Group (parent)
IPO Outlook / Plans
Listed on KRX as 207940 (Samsung Biologics) — public on KOSPI
Upcoming Milestones & Key Dates
Q3 2026
Manufacturing
Plant 5 commercial ramp + S5 revenue recognition
Q4 2026
M&A
PolyPeptide acquisition close ($1.8B)
Late 2026
Manufacturing
Bio Campus II groundbreaking / first-pour
Clinical Development Pipeline
Plant 5 (Songdo, S5)
Target: mAb / bispecifics / ADCsBio Campus II
Target: Multi-modality biologicsSamsung Bioepis biosimilars (partner)
Target: BiosimilarsRecent News
Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPeptide
Samsung Bio set to launch $1.8B buyout of Swiss CDMO PolyPeptide.
Leadership Team
John Rim
Chief Executive Officer
James Choi
Chief Financial Officer
Tae-Han Kim
Chief Technology Officer
Careers & Job Openings